Incidence of Second Primary Malignancies after Autologous Transplantation for Multiple Myeloma in the Era of Novel Agents

Firoozeh Sahebi , Simona Iacobelli (1) , Giulia Sbianchi , Linda Koster (2) , Didier Blaise (3, 4) , Peter Remenyi , Nigel H. Russell (5) , Per Ljungman (6) , Guido Kobbe , Jane Apperley (7) , Marek Trneny (8) , Marta Krejci (9) , Wieslaw Wiktor-Jedrzejczak (10) , James F. Sanchez , Nicolaas Schaap , Cecilia Isaksson , Stig Lenhoff (11) , Paul Browne (12) , Christof Scheid (13) , Keith M. O. Wilson , Ibrahim Yakoub-Agha (14, 15) , Soledad Gonzalez Muniz , Stefan Schoenland , Curly Morris (16) , Laurent Garderet (17) , Nicolaus Kroeger (18)

1 University of Rome TorVergata
2 EBMT - European Society for Blood and Marrow Transplantation
3 Service d’Hématologie [Institut Paoli Calmettes, Marseille]
4 CRCM - Centre de Recherche en Cancérologie de Marseille
5 Department of Clinical Haematology
6 Dept. of Hematology
7 Department of Haematology
8 Charles University Hospital
9 University Hospital Brno
10 Department of Hematology, Oncology and Internal Diseases
11 Department of Hematology
12 Trinity College Dublin
13 Department I of Internal Medicine
14 CHRU Lille - Centre Hospitalier Régional Universitaire [CHU Lille]
15 LIRIC - Lille Inflammation Research International Center - U 995
16 QUB - Queen's University [Belfast]
17 CHU Saint-Antoine [AP-HP]
18 University Hospital Hamburg-Eppendorf

The advent of novel agents for multiple myeloma (MM) is cause for a re-examination of the incidence of second primary malignancies (SPM5). We examined the SPM rate in MM patients who were enrolled in the prospective observational CALM (Collaboration to Collect Autologous Transplant outcome in Lymphoma and Myeloma) study. Between 2008 and 2012, 3204 patients with MM underwent a first autologous hematopoietic stem cell transplantation. Plerixafor was used as a mobilizing agent for patients with poor (or potentially poor) stem cell mobilization as defined by the respective centers. A total of 135 patients developed SPM5, with a cumulative incidence of 5.3% (95% confidence interval, 4.4 to 6.3) at 72 months. Ninety-four patients developed solid tumors, 30 developed hematologic malignancies, and 11 developed an SPM of an unknown type. The cumulative incidence of known hematologic and solid malignancies were 1.4% and 3.6%, respectively, at 72 months. In a univariate analysis, use of radiotherapy, type of induction regimen, hematopoietic stem cell dose, poor mobilizer status, plerixafor use, and sex did not influence the cumulative incidence of SPMs. Only age over 65 years was statistically associated with an increased incidence. Overall, the incidence of SPMs was comparable to earlier estimations of SPMs in MM. (C) 2018 American Society for Blood and Marrow Transplantation.

Domaines: Sciences du Vivant [q-bio]

Firoozeh Sahebi, Simona Iacobelli, Giulia Sbianchi, Linda Koster, Didier Blaise, et al.. Incidence of Second Primary Malignancies after Autologous Transplantation for Multiple Myeloma in the Era of Novel Agents. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2018, 24 (5), pp.930-936. ⟨10.1016/j.bbmt.2018.01.006⟩. ⟨hal-02143580⟩